Leukemia & Lymphoma
Volume 62, 2021 - Issue 9
Letters to the Editor
Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center
Cecilia Carpioa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain
https://orcid.org/0000-0001-9346-0134
https://orcid.org/0000-0001-9346-0134, , Guillermo Villacampac Oncology Data Science (OdysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spainhttps://orcid.org/0000-0003-4868-6585
https://orcid.org/0000-0003-4868-6585, , , , , , , , , David Valcárcela Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spainhttps://orcid.org/0000-0002-8747-078X
https://orcid.org/0000-0002-8747-078X, , Francesc Boscha Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spainhttps://orcid.org/0000-0001-9241-2886
https://orcid.org/0000-0001-9241-2886 & Pere Barbaa Department of Hematology, Vall d'Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital (HUVH), Universitat Autònoma de Barcelona, Barcelona, Spain;b Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainCorrespondence[email protected]
https://orcid.org/0000-0001-7076-7969
https://orcid.org/0000-0001-7076-7969 show all